J&J Unit Infringed Blood Cancer Patent, US Gov't Says
The U.S. has accused a Johnson & Johnson subsidiary of infringing a U.S. government patent covering a blood cancer treatment, stepping up its response amid an ongoing claim that the patent...To view the full article, register now.
Already a subscriber? Click here to view full article